Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Announces FDA Approves IND Application to Develop KRAS G12C Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$65.0 million","upfrontCash":"$45.0 million","newsHeadline":"Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Announces First Patient Dosed in Phase I\/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobio Announces Clinical Collaboration To Evaluate CD73 Monoclonal Antibody JAB-BX102 In Combination With KEYTRUDA\u00ae (pembrolizumab) For Patients With Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Jacobio Regains Global Rights to SHP2 Inhibitors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Jacobio Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jacobio Pharma Announced its KRAS G12C Inhibitor Reached the Primary Endpoint","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Jacobio Pharma

    Menu

    Jacobio Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Jacobio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Pharma Announced its KRAS G12C Inhibitor Reached the Primary Endpoint

              Details:

              JAB-21822 (glecirasib) is a KRAS G12C inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of KRAS G12C mutated pancreatic cancer.

              Lead Product(s): Glecirasib

              Therapeutic Area: Oncology Product Name: JAB-21822

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S.

              Details:

              JAB-30300 is an orally bioavailable small molecule, P53 Y220C activator, which is being evaluated for the treatment of patients with solid tumors harboring P53 Y220C mutation.

              Lead Product(s): JAB-30300

              Therapeutic Area: Oncology Product Name: JAB-30300

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

              Details:

              JAB-3312 is a highly selective SHP2 allosteric inhibitor, in combination with JAB-21822 (glecirasib), a KRAS G12C inhibitor is being evaluated for first-line non-small cell lung cancer patients with KRAS G12C mutations.

              Lead Product(s): JAB-3312,Glecirasib

              Therapeutic Area: Oncology Product Name: JAB-3312

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer

              Details:

              JAB-21822 (glecirasib) is a KRAS G12C inhibitor developed by Jacobio and being developed in KRAS G12C-mutated locally advanced or metastatic pancreatic cancer patients.

              Lead Product(s): Glecirasib,JAB-3312

              Therapeutic Area: Oncology Product Name: JAB-21822

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Regains Global Rights to SHP2 Inhibitors

              Details:

              Through the termination, Jacobio will regain the global rights previously granted to AbbVie for SHP2 inhibitor, JAB-3312, including decision-making authority over all development, commercialization, manufacturing, regulatory activities relating to SHP2 inhibitors globally.

              Lead Product(s): JAB-3312

              Therapeutic Area: Oncology Product Name: JAB-3312

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: AbbVie Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Termination July 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China

              Details:

              Glecirasib is a novel KRAS G12C inhibitor. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors harbouring KRAS G12C mutation, including a pivotal clinical trial int NSCLC in China.

              Lead Product(s): Glecirasib,JAB-3312

              Therapeutic Area: Oncology Product Name: JAB-21822

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Announces Clinical Collaboration To Evaluate CD73 Monoclonal Antibody JAB-BX102 In Combination With KEYTRUDA® (pembrolizumab) For Patients With Cancer

              Details:

              Under the terms of the agreement, the clinical study will evaluate the clinical effect of JAB-BX102, a CD73 monoclonal antibody in combination with KEYTRUDA (pembrolizumab), provided by merck, for the treatment of advanced solid tumors.

              Lead Product(s): JAB-BX102,Pembrolizumab

              Therapeutic Area: Oncology Product Name: JAB-BX102

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting

              Details:

              JAB-2485 is a highly selective small molecule Aurora A inhibitor. Preclinical data show that JAB-2485 is highly selective at biochemical and cellular levels. It has potential to benefit patients with small cell lung cancer and triple-negative breast cancer.

              Lead Product(s): JAB-2485

              Therapeutic Area: Oncology Product Name: JAB-2485

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Pharma to Collaborate with Merck on Clinical Trial of JAB-21822 in Combination with Cetuximab

              Details:

              JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors.

              Lead Product(s): JAB-21822,Cetuximab

              Therapeutic Area: Oncology Product Name: JAB-21822

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Jacobio Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jacobio Receives CDE Approval for KRAS G12C Inhibitor JAB-218822's Phase II Pivotal Study in China

              Details:

              JAB-21822 is KRAS G12C inhibitor independently. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.

              Lead Product(s): JAB-21822

              Therapeutic Area: Oncology Product Name: JAB-21822

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 06, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY